{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:39:40Z","timestamp":1792100380888,"version":"4.4.0"},"reference-count":22,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T00:00:00Z","timestamp":1645228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) significantly improve the outcomes of patients with advanced clear cell renal cell carcinoma (ccRCC); however, high-grade toxicities can occur, particularly during combination therapy. Herein, we report a patient with advanced metastatic ccRCC, who developed grade 4 cholestasis during combined therapy with nivolumab and cabozantinib. After the exclusion of common disorders associated with cholestasis and a failure of corticosteroids (CS), a liver biopsy was performed that demonstrated severe ductopenia. Consequently, a diagnosis of vanishing bile duct syndrome related to TKI and ICI administration was made, resulting in CS discontinuation and ursodeoxycholic acid administration. After a 7-month follow-up, liver tests had returned to normal values. Immunological studies revealed that our patient had developed robust T-cells and macrophages infiltrates in his lung metastasis, as well as in skin and liver tissues at the onset of toxicities. At the same time, peripheral blood immunophenotyping revealed significant changes in T-cell subsets, suggesting their potential role in the pathophysiology of the disease.<\/jats:p>","DOI":"10.3390\/diagnostics12020539","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T08:14:46Z","timestamp":1645431286000},"page":"539","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma"],"prefix":"10.3390","volume":"12","author":[{"given":"Karim","family":"Gourari","sequence":"first","affiliation":[{"name":"Department of Oncology, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8825-8126","authenticated-orcid":false,"given":"Julien","family":"Catherine","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, CUB H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"},{"name":"Institute for Medical Immunology, Universit\u00e9 Libre de Bruxelles, 6041 Gosselies, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soizic","family":"Garaud","sequence":"additional","affiliation":[{"name":"Molecular Immunology Unit, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kerger","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Lepida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aspasia","family":"Georgala","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Lebrun","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gomez Galdon","sequence":"additional","affiliation":[{"name":"Department of Pathology, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Gil","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1150-1295","authenticated-orcid":false,"given":"Karen","family":"Willard-Gallo","sequence":"additional","affiliation":[{"name":"Molecular Immunology Unit, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0504-7671","authenticated-orcid":false,"given":"Mireille","family":"Langouo Fontsa","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"},{"name":"Molecular Immunology Unit, Institut Jules Bordet, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","article-title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update","volume":"94","author":"Choueiri","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s40425-019-0813-8","article-title":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)","volume":"7","author":"Rini","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e000185","DOI":"10.1136\/esmoopen-2017-000185","article-title":"New treatment options for metastatic renal cell carcinoma","volume":"2","author":"Hutson","year":"2017","journal-title":"ESMO Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-17-1299","article-title":"Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies","volume":"17","author":"Makhov","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","article-title":"Hepatotoxicity of tyrosine kinase inhibitors: Clinical and regulatory perspectives","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e000268","DOI":"10.1136\/esmoopen-2017-000268","article-title":"Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury","volume":"2","author":"Doherty","year":"2017","journal-title":"ESMO Open"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3389\/fphar.2019.01173","article-title":"Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review","volume":"10","author":"Gao","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1200\/JCO.2021.39.6_suppl.302","article-title":"Efficacy of avelumab plus axitinib (A + Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101","volume":"39","author":"Tomita","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cld.2007.11.007","article-title":"Vanishing bile duct syndrome","volume":"12","author":"Reau","year":"2008","journal-title":"Clin. Liver Dis."},{"key":"ref_13","first-page":"10339","article-title":"Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab","volume":"27","author":"Zhong","year":"2020","journal-title":"Can. J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.critrevonc.2014.11.006","article-title":"Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials","volume":"93","author":"Ghatalia","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2169\/internalmedicine.9851-17","article-title":"Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma","volume":"57","author":"Matsubara","year":"2018","journal-title":"Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41424-018-0049-9","article-title":"Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis","volume":"9","author":"Reddy","year":"2018","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1159\/000507695","article-title":"Fatal Cholestatic Liver Injury during Treatment with PD1 Immune Checkpoint Inhibitor for Malignant Melanoma: A Case Report","volume":"13","author":"Thorsteinsdottir","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1007\/s42399-021-00803-9","article-title":"Pembrolizumab-Induced Vanishing Bile Duct Syndrome: A Case Report","volume":"3","author":"Masetti","year":"2021","journal-title":"SN Compr. Clin. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis with Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1158\/1078-0432.CCR-18-3206","article-title":"irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial","volume":"25","author":"Pignon","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-018-0328-8","article-title":"Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients","volume":"6","author":"Subrahmanyam","year":"2018","journal-title":"J. Immunother. Cancer"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/2\/539\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:23:12Z","timestamp":1760134992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/2\/539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,19]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["diagnostics12020539"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics12020539","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202201.0298.v1","asserted-by":"object"}]},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,19]]}}}